A Cross-Sectional Study Comparing Mir-503-5p Expression in Gastric Cancer Patients Before and After Chemotherapy

Document Type : Research/Original Article

Authors

1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Student research committee, Shiraz university of Medical sciences, Shiraz, Iran.

3 Department of Immunology School of Medicine Shiraz university of Medical sciences, Shiraz, Iran. Cancer Immunology & Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Background: Gastric cancer is the third most fatal cancer among all cancer types. Early diagnosis of this
cancer dramatically increases the five-year survival rate of patients. MicroRNAs (miRNAs) play a significant
role in tumorigenesis, angiogenesis, invasion, metastasis, and drug resistance in gastric cancer, similar to other
cancers. The expression levels of miRNAs can influence tumor progression or suppression. This study aimed
to investigate the expression levels of miR-503-5p in the serum of gastric cancer patients both before and after
chemotherapy.
Methods: This observational study was conducted from 2022 to 2024 at Namazi and Shahid Faghihi Hospitals.
Thirty patients with gastric cancer with a definitive diagnosis by gastroenterologists and pathologists and had
not received any prior treatment, were included in the study. A blood sample of 5 ml was drawn from each patient
and sent to the laboratory for analysis. After the completion of thechemotherapy, blood samples were collected
again. The expression level of miR-503-5p was measured using real-time PCR. Data analysis was performed
using SPSS version 24, and differences in miR-503-5p expression and clinicopathological characteristics were
assessed using ANCOVA and paired ttests.
Results: Comparing serum levels of miR-503-5p in gastric cancer patients before and after chemotherapy
revealed a 2.12-fold increase in miR-503-5p expression post-treatment (P=0.001). Furthermore, expression
levels of miR-503-5p in the serum of patients with metastasis were significantly lower than patients without
metastasis (P<0.05).
Conclusion: Considering the increased expression of miR-503-5p following treatment in gastric cancer patients,
these findings suggest a suppressive role for miR-503-5p in gastric cancer. miR-503-5p may potentially serve as
a biomarker for evaluating gastric cancer treatment.

Highlights

Seyedeh Azra Shamsdin (Google Scholar)

Hassan Akrami (Google Scholar)

Keywords

References

1. Thrumurthy SG, Chaudry MA,
Hochhauser D, Mughal M. The
diagnosis and management of gastric
cancer. Bmj. 2013;347.
2. Karimi P, Islami F, Anandasabapathy
S, Freedman ND, Kamangar F. Gastric
cancer: descriptive epidemiology, risk
factors, screening, and prevention.
Cancer epidemiology, biomarkers &
prevention. 2014;23(5):700-13.
3. Clinton SK, Giovannucci EL, Hursting
SD. The world cancer research fund/
American institute for cancer research
third expert report on diet, nutrition,
physical activity, and cancer: impact
and future directions. The Journal of
nutrition. 2020;150(4):663-71.
4. Lauren P. Diffuse and so-called
intestinal type carcinoma: an
attempt at histological classification.
Acta Pathol Microbiol Scand.
1965;64:31-49.
5. Bray F, Laversanne M, Sung H,
Ferlay J, Siegel RL, Soerjomataram
I, et al. Global cancer statistics
2022: GLOBOCAN estimates of
incidence and mortality worldwide
for 36 cancers in 185 countries.
CA: a cancer journal for clinicians.
2024;74(3):229-63.
6. Chiba T, Marusawa H, Seno H,
Watanabe N. Mechanism for gastric
cancer development by Helicobacter
pylori infection. Journal of
gastroenterology and hepatology.
2008;23(8pt1):1175-81.
7. Guo Y, Zhang Y, Gerhard M, Gao
J-J, Mejias-Luque R, Zhang L, et
al. Effect of Helicobacter pylori
on gastrointestinal microbiota: a
population-based study in Linqu, a
high-risk area of gastric cancer. Gut.
2020;69(9):1598-607.
8. Ferlay J, Ervik M, Lam F, Colombet
M, Mery L, Piñeros M, et al. Global
cancer observatory: cancer today.
Lyon, France: international agency
for research on cancer. 2018.
9. van Der Kaaij RT, Koemans WJ,
van Putten M, Snaebjornsson P,
Luijten JC, van Dieren JM, et al. A
population-based study on intestinal
and diffuse type adenocarcinoma
of the oesophagus and stomach in
the Netherlands between 1989 and
2015. European Journal of Cancer.
2020;130:23-31.
10. Kim Y, Jun JK, Choi KS, Lee H-Y,
Park E-C. Overview of the National
Cancer screening programme and
the cancer screening status in Korea.
2011.
11. Hamashima C, Group SR, Guidelines
GDGfGCS. Update version of the
Japanese guidelines for gastric cancer
screening. Japanese journal of clinical
oncology. 2018;48(7):673-83.
12. Facciorusso A, Antonino M, Di
Maso M, Muscatiello N. Endoscopic
submucosal dissection vs endoscopic
mucosal resection for early gastric
cancer: A meta-analysis. World
journal of gastrointestinal endoscopy.
2014;6(11):555.
13. Son T, Hyung WJ. Laparoscopic
gastric cancer surgery: current
evidence and future perspectives.
World Journal of Gastroenterology.
2016;22(2):727.
14. Machlowska J, Baj J, Sitarz M,
Maciejewski R, Sitarz R. Gastric
cancer: epidemiology, risk factors,
classification, genomic characteristics
and treatment strategies. International
journal of molecular sciences.
2020;21(11):4012.
15. Xu D-z, Geng Q-r, Tian Y, Cai M-y,
Fang X-j, Zhan Y-q, et al. Activated
mammalian target of rapamycin is a
potential therapeutic target in gastric
cancer. BMC cancer. 2010;10:1-10.
16. Ambros V. The functions of
animal microRNAs. Nature.
2004;431(7006):350-5.
17. Reda El Sayed S, Cristante J, Guyon
L, Denis J, Chabre O, Cherradi N.
MicroRNA therapeutics in cancer:
current advances and challenges.
Cancers. 2021;13(11):2680.
18. Calin GA, Dumitru CD, Shimizu
M, Bichi R, Zupo S, Noch E, et
al. Frequent deletions and down-
regulation of micro-RNA genes
miR15 and miR16 at 13q14 in chronic
lymphocytic leukemia. Proceedings
of the national academy of sciences.
2002;99(24):15524-9.
19. Hanahan D, Weinberg RA. Hallmarks
of cancer: the next generation. cell.
2011;144(5):646-74.
20. Lin S, Gregory RI. MicroRNA
biogenesis pathways in cancer. Nature
reviews cancer. 2015;15(6):321-33.
21. Hata A, Kashima R. Dysregulation
of microRNA biogenesis machinery
in cancer. Critical reviews in
biochemistry and molecular biology.
2016;51(3):121-34.
22. Cholewinski G, Waluga M. The role of
microRNAs in carcinogenesis and the
utility of microRNA determination
in diagnosis of gastric cancer
development. J Physiol Pharmacol.
2022;73(6).
23. Rupaimoole R, Calin GA, Lopez-
Berestein G, Sood AK. miRNA
deregulation in cancer cells and the
tumor microenvironment. Cancer
discovery. 2016;6(3):235-46.
24. Li W, Li J, Mu H, Guo M, Deng H.
MiR-503 suppresses cell proliferation
and invasion of gastric cancer by
targeting HMGA2 and inactivating
WNT signaling pathway. Cancer Cell
International. 2019;19:1-12.
25. Tan B, Li Y, Di Y, Fan L, Zhao
Q, Liu Q, et al. Clinical value of
peripheral blood microRNA detection
in evaluation of SOX regimen as
neoadjuvant chemotherapy for gastric
cancer. Journal of clinical laboratory
analysis. 2018;32(4):e22363.
26. Livak KJ, Schmittgen TD. Analysis
of relative gene expression data
using real-time quantitative PCR
and the 2− ΔΔCT method. methods.
2001;25(4):402-8.
27. Peng Y, Liu YM, Li LC, Wang LL,
Wu XL. microRNA-503 inhibits
gastric cancer cell growth and
epithelial-to-mesenchymal transition.
Oncology letters. 2014;7(4):1233-8.
28. Wu D, Cao G, Huang Z, Jin K, Hu
H, Yu J, et al. Decreased miR-503
expression in gastric cancer is
inversely correlated with serum
carcinoembryonic antigen and acts as
a potential prognostic and diagnostic
biomarker. OncoTargets and therapy.
2016:129-35.
Iranian Journal of Colorectal Research
Volume 12, Issue 4
December 2024
Pages 117-122

Files

Share

How to cite

Statistics